263 related articles for article (PubMed ID: 12857950)
21. Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3.
Zander C; Takahashi J; El Hachimi KH; Fujigasaki H; Albanese V; Lebre AS; Stevanin G; Duyckaerts C; Brice A
Hum Mol Genet; 2001 Oct; 10(22):2569-79. PubMed ID: 11709544
[TBL] [Abstract][Full Text] [Related]
22. Binding surface mapping of intra- and interdomain interactions among hHR23B, ubiquitin, and polyubiquitin binding site 2 of S5a.
Ryu KS; Lee KJ; Bae SH; Kim BK; Kim KA; Choi BS
J Biol Chem; 2003 Sep; 278(38):36621-7. PubMed ID: 12832454
[TBL] [Abstract][Full Text] [Related]
23. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates.
Zhong X; Pittman RN
Hum Mol Genet; 2006 Aug; 15(16):2409-20. PubMed ID: 16822850
[TBL] [Abstract][Full Text] [Related]
24. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3.
Berke SJ; Chai Y; Marrs GL; Wen H; Paulson HL
J Biol Chem; 2005 Sep; 280(36):32026-34. PubMed ID: 16040601
[TBL] [Abstract][Full Text] [Related]
25. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
26. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.
Wang HL; Hu SH; Chou AH; Wang SS; Weng YH; Yeh TH
Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954
[TBL] [Abstract][Full Text] [Related]
27. p62/sequestosome 1 regulates aggresome formation of pathogenic ataxin-3 with expanded polyglutamine.
Zhou L; Wang H; Chen D; Gao F; Ying Z; Wang G
Int J Mol Sci; 2014 Aug; 15(9):14997-5010. PubMed ID: 25158237
[TBL] [Abstract][Full Text] [Related]
28. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
29. Structure and functional properties of the ubiquitin binding protein p62.
Geetha T; Wooten MW
FEBS Lett; 2002 Feb; 512(1-3):19-24. PubMed ID: 11852044
[TBL] [Abstract][Full Text] [Related]
30. The ubiquitin-proteasome pathway is required for the function of the viral VP16 transcriptional activation domain.
Zhu Q; Yao J; Wani G; Chen J; Wang QE; Wani AA
FEBS Lett; 2004 Jan; 556(1-3):19-25. PubMed ID: 14706819
[TBL] [Abstract][Full Text] [Related]
31. Structural and functional analysis of ataxin-2 and ataxin-3.
Albrecht M; Golatta M; Wüllner U; Lengauer T
Eur J Biochem; 2004 Aug; 271(15):3155-70. PubMed ID: 15265035
[TBL] [Abstract][Full Text] [Related]
32. [Mechanisms to control degradation of polyglutamine-containing protein].
Nakayama K
Rinsho Shinkeigaku; 2003 Nov; 43(11):906-8. PubMed ID: 15152500
[TBL] [Abstract][Full Text] [Related]
33. Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease.
Takahashi J; Tanaka J; Arai K; Funata N; Hattori T; Fukuda T; Fujigasaki H; Uchihara T
J Neuropathol Exp Neurol; 2001 Apr; 60(4):369-76. PubMed ID: 11305872
[TBL] [Abstract][Full Text] [Related]
34. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
35. Interaction of the ring finger-related U-box motif of a nuclear dot protein with ubiquitin-conjugating enzymes.
Pringa E; Martinez-Noel G; Muller U; Harbers K
J Biol Chem; 2001 Jun; 276(22):19617-23. PubMed ID: 11274149
[TBL] [Abstract][Full Text] [Related]
36. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
37. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
38. Impairment of the ubiquitin-proteasome system by protein aggregation.
Bence NF; Sampat RM; Kopito RR
Science; 2001 May; 292(5521):1552-5. PubMed ID: 11375494
[TBL] [Abstract][Full Text] [Related]
39. Functional interactions as a survival strategy against abnormal aggregation.
Masino L; Nicastro G; Calder L; Vendruscolo M; Pastore A
FASEB J; 2011 Jan; 25(1):45-54. PubMed ID: 20810784
[TBL] [Abstract][Full Text] [Related]
40. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses.
Moore DJ; Dawson VL; Dawson TM
Neuromolecular Med; 2003; 4(1-2):95-108. PubMed ID: 14528055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
